

D. Benfaremo², F. Proft⁵, D. Poddubnyy⁵, G. Moroncini². ¹Azienda Ospedali Riuniti delle Marche, Medical Clinic and Internal Medicine Residency Programme, Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Ancona, Italy; ²Azienda Ospedali Riuniti delle Marche, Medical Clinic, Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Ancona, Italy; ³Azienda Ospedali Riuniti delle Marche, Radiology Clinic, Department of Radiological Sciences, Ancona, Italy; ⁴Azienda Ospedali Riuniti delle Marche, Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Italy; ⁵Charité Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany

Background: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease characterized by different domains.[1] Interest is growing towards early diagnosis of axial PsA (AxPsA), to allow better disease characterization and well-timed targeted therapeutic strategies.

Objectives: In this study, we report preliminary results of a rheumatological screening strategy settled in a dermatological centre. Primary objective is to validate the screening tool in a cohort of Italian patients affected by psoriasis, improving early diagnosis of AxPsA. Secondary objectives are: 1. classification and characterization of axial involvement; 2. profiling of patients' characteristics and comorbidities.

Methods: Patients were enrolled in the ATTRACT study (Axial psoriatic arThritis scReening AnCona iTaly) according to the following inclusion criteria: 1. age > 18 years; 2. diagnosis of psoriasis (Pso) by a dermatologist; 3. capacity to understand and sign the informed consent. Patients who assumed any DMARD 12 weeks prior to screening were excluded. Study design is shown in Figure 1. The Dermatologic-Centred Screening (DCS) tool[2], recently validated for early identification of AxPsA, was translated in Italian and administered to outpatients in the dermatological clinic. Patients were divided in the following groups based on answers to the Inflammatory Back Pain (IBP) related questions of the DCS: **A.** no affirmative answers (low AxPsA probability); **B.** all affirmative answers (high probability); **C.** only two affirmative answers (intermediate probability). Group B & C patients underwent complete rheumatological examination comprehensive of clinimetric, laboratoristic and genetic data; X-ray and MRI imaging of the whole spine and pelvis were performed in all of them classifying in: **a.** confirmed AxPsA; **b.** peripheral PsA involvement only; **c.** PsA excluded.

Results: N.366 patients were screened; n.101 met exclusion criteria. N.91 (34.3%) were classified as group A, n.125 (47.2%) as group B, n.49 (18.5%) as group C. Following characteristics were notable: a. female sex more represented in group B; b. mean age higher in group C; c. onychopathy more represented in group A & C. List of patients' clinical characteristics is shown in Table 1 Among group B patients, n.28 (22.4% - B1) were classified as PsA excluded; n.22 (17.6% - B2) as isolated per-PsA (according to CASPAR criteria), n.39 (31.2% - B3) as AxPsA (n.34 fulfilling ASAS criteria, n.31 with concomitant per-PsA). Among group C, n.15 (30.6% - C1) as PsA excluded; n.3 (6.1% - C2) as isolated per-PsA, n.5 (10.2% - C3) as AxPsA (n.4 fulfilling ASAS, n.5 with concomitant per-PsA). N.13 patients are still awaiting results of imaging; n.49 (n.24 group B, n.25 group C) refused to undergo imaging and were considered lost at follow-up.

Conclusion: The DCS tool may be useful for PsA screening in a real-life cohort of Pso patients, an Inflammatory Back Pain was reported by about half of the screened Pso patients. This tool helped to identify a substantial number of naïve patients not only affected by AxPsA but also by peripheral PsA in a purely dermatological setting.

REFERENCES:

- [1] Coates LC et al. *Nat Rev Rheumatol* 2022
- [2] Proft F, et al. *Ann Rheum Dis* 2022

Table 1. Comparison between clinical characteristics of patients in groups A, B and C.

	Group A (n.91)	Group B (n.125)	Group C (n.49)	p
Gender (F/M), n(%)	35(38.5)/56(61.5)	76(60.8)/49(39.2)	20(40.8)/29(59.2)	0.002
Age, yrs	51.49±17.33	49.15±15.65	59.57±17.9	0.0012
PASI*	3.71±5.38	3.33±6.35	1.73±2.73	0.171
Onychopathy, y/n, n(%)	30 (46.2)/35 (53.8)	76(69.7)/33(30.3)	24(66.7)/12(33.3)	0.007
Cardiovascular diseases	32 (59.3)	36 (42.9)	22 (59.5)	0.124
Metabolic diseases	33 (61.1)	52 (61.9)	23 (62.2)	0.476
Infections	1 (1.9)	3 (3.6)	0 (0.0)	0.670
Neurologic/Psychiatric	4 (7.4)	7 (8.3)	3 (8.1)	0.877
Back pain duration > 3 months (question 3a), n(%)	0 (0.0)	125(100)	34(69.4)	<
Back pain start before age of 45 (question 3b), n(%)	0 (0.0)	125(100)	15(30.6)	<
				0.001




Figure 1. Design of the study

Acknowledgements: NIL.

Disclosure of Interests: None Declared.

DOI: 10.1136/annrheumdis-2023-eular.2233

POS0879

THE IMPACT OF 6-MONTH DELAY IN DIAGNOSIS ON CLINICAL AND FUNCTIONAL STATUS IN THE PSA PATIENTS UNDER bDMARD TREATMENT: RESULTS FROM TREASURE DATABASE

Keywords: Registries, Psoriatic arthritis, Real-world evidence

G. Ayan¹, L. Kılıç¹, N. S. Yasar Bilge², P. Atagündüz³, E. Dalkılıç⁴, Y. Pehlivan⁴, O. Küküşahin⁵, C. Bes⁶, S. Akar⁷, M. Çınar⁸, H. Emmungil⁹, D. Ersözlu¹⁰, A. Ates¹¹, R. Mercan¹², G. Kimyon¹³, S. S. Koca¹⁴, E. Gönüllü¹⁵, V. Yazısız¹⁶, N. A. Kanitez¹⁷, A. Erden¹⁸, B. Yağız⁴, B. N. Coşkun⁴, T. Kaşifoğlu², A. İ. Ertenli¹, S. Kıraz¹, U. Kalyoncu¹. ¹Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; ²Eskisehir Osmangazi University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Eskisehir, Turkey; ³Marmara University, Medical Faculty, Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey; ⁴Uludağ University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Bursa, Turkey; ⁵Ankara Yıldırım Beyazıt University, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; ⁶Istanbul Basaksehir Cam and Sakura City Hospital, Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey; ⁷Izmir Katip Celebi University, Department of Internal Medicine Division of Rheumatology, Izmir, Turkey; ⁸University of Health Sciences, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; ⁹Trakya University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Tekirdag, Turkey; ¹⁰Adana City Training and Research Hospital, Department of Internal Medicine Division of Rheumatology, Adana, Turkey; ¹¹Ankara University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; ¹²Namik Kemal University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; ¹³Mustafa Kemal University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Hatay, Turkey; ¹⁴Firat University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Elazığ, Turkey; ¹⁵Sakarya University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Sakarya, Turkey; ¹⁶Akdeniz University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Antalya, Turkey; ¹⁷Koc University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey; ¹⁸Ankara City Hospital, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey

Background: The impact of delay in diagnosis on the disease severity and functional loss has been shown previously in Psoriatic arthritis (PsA) patients.

Objectives: This study aimed to evaluate the impact of 6 month-delay in diagnosis on patients' clinical outcomes and functional outcomes in the PsA patients under bDMARD therapy using a national database.

Methods: TReasure is a national, multicentre, longitudinal, and observational database, initiated in Turkey in 2017 and now includes 17 centres [1]. PsA patients with/out more than 6 months from the onset of symptoms to diagnosis were evaluated. Demographic characteristics of the patients (age, gender, delay in diagnosis), smoking (ever), BMI, and CCI score were calculated. PsA and associated disease characteristics; dactylitis, enthesitis, uveitis, IBD, sacroiliitis by mNY, disease activity at bDMARD initiation; SJC (66 joints), TJC (68 joints), ASDAS-CRP, ASDAS-ESR, BASDAI, ESR, CRP, VAS (physician global, patient global), function and quality of life; BASFI (>40 mm), HAQ-DI (<0.5, 0.5-1.0, >1.0), EQ5D, were assessed and compared between two groups.

Results: In TReasure database, the time between symptom to diagnosis was known in 865/911 (94.9%) of PsA patients. More than 6 months of delay in diagnosis was present in 627/865 (72.4%) patients. In delayed-diagnosis group time from symptom onset to initiation of bDMARD was longer (6.1 (3.3-6.1) vs 2.4 (0.8-7.1) years, $p<0.001$). Patients with delay in diagnosis of PsA had more sacroiliitis (57.3% vs 46.2%, $p=0.014$) according to mNY criteria. However, dactylitis was more common in patients with less than 6 months of delay in diagnosis (31.2% vs 19.1%, $p<0.001$). Patients' ASDAS-CRP and VAS-Physician Global score were slightly higher, while other activity parameters were similar; (ASDAS-ESR, BASDAI, BASMI, VAS patient global, SJC and TJC) (Table 1). There was no difference between the median (IQR) BASFI and HAQ-DI scores in delayed-diagnosis group, whereas BASFI and HAQ-DI categories showed worse function and quality of life. EQ5D showed similar result with slightly worse scores in delayed-diagnosis group.

Conclusion: Approximately three-quarters of PsA patients using bDMARDs have a delay of at least 6 months in diagnosis. Delay in diagnosis significantly prolongs the time until bDMARD initiation. The most important clinical finding in earlier diagnosis group is dactylitis. Axial involvement may be a reason, perhaps the result, of the delay in diagnosis. Since the delay in diagnosis is related to poor function and quality of life, efforts should be made for early diagnosis at every stage.

REFERENCE:

[1] Kalyoncu U, et al. *Turk J Med Sci*. 2018 Aug 16;48(4):856-861.

Table 1. Demographic and Clinical Characteristics of Patients with/without diagnostic delay

	Patients with diagnostic delay < 6 months n=238	Patients with diagnostic delay > 6 months N=627	P
Current Age (y)	45 (38-57)	47 (40-57)	0.09
Gender (male) n, (%)	89 (37.4)	200 (31.9)	0.13
Delay in diagnosis, month	3.0 (1.0-4.9)	24.0 (11.9-61.0)	<0.001
Disease duration (symptom-bDMARD initiation)	2.4 (0.8-7.1)	6.1 (3.3-6.1)	<0.001
Disease duration (diagnosis-bDMARD initiation)	2.3 (0.6-7.1)	2.5 (0.7-6.2)	0.61
BMI	28.1 (24.6-32.0)	28.0 (24.9-31.9)	0.62
Smoking (ever)	119 (50.6)	289 (47.2)	0.37
CCI (≥ 1), n (%)	47 (19.7)	127 (20.3)	0.62
ASDAS-CRP	3.45 (2.77-4.08)	3.62 (3.14-4.25)	0.011
BASFI Score (0-10)	4.6 (2.2-6.2)	4.7 (3.4-5.9)	0.52
BASFI category > 4	92 (61.7)	307 (71.4)	0.028
EQ5D score	11 (9-11)	11 (10-12)	0.026
HAQ-DI score	0.64 (0.40-1.0)	0.63 (0.50-0.80)	0.76
HAQ-DI category	37 (28.0)	68 (17.6)	0.002
<0.5	58 (43.9)	241 (62.4)	
0.5-1.0	37 (28.0)	77 (19.9)	
> 1.0			
VAS-Physician global	70 (50-80)	70 (60-80)	0.003
Sacroiliitis according to mNY, n (%)	80 (46.2)	238 (57.3)	0.014
Dactylitis, n (%)	64 (31.2)	105 (19.1)	<0.001

Continuous variables were presented as median (%25-75), BMI: Body mass index (n=856), CCI: Charlson Comorbidity Index (n=865), BASFI: The Bath

Acknowledgements: NIL.

Disclosure of Interests: None Declared.

DOI: 10.1136/annrheumdis-2023-eular.3194

POS0880

COMPARATIVE DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: DATA FROM COVAD PATIENT-REPORTED E-SURVEY

Keywords: Psoriatic arthritis, Rheumatoid arthritis, Spondyloarthritis

V. Venerito¹, M. Fornaro¹, F. Iannone¹, L. Cavagna², M. Kuwana³, V. Agarwal⁴, N. Ravichandran⁵, J. Day^{6,7,8}, M. Joshi⁹, S. Saha¹⁰, S. S. Shaharir¹¹, W. Katchamart¹², P. A. Goo¹³, L. Trabocco¹⁴, Y. M. Chen^{15,16}, P. Sen¹⁷, J. B. Lilleker^{18,19}, A. Nune²⁰, J. Pauling^{21,22}, C. Wincup^{23,24}, A. L. Tan^{25,26}, N. Ziade^{27,28}, M. Milchert²⁹, A. E. Gracia-Ramos³⁰, C. Vinicio Caballero³¹,

C. Study³², V. Agarwal⁵, R. Aggarwal³³, L. Gupta^{5,18,34,35}. ¹University of Bari "Aldo Moro"; Rheumatology Unit - Department of Regenerative and Precision Medicine and Ionian Area, Bari, Italy; ²Università degli Studi di Pavia, Rheumatology Unit, Dipartimento di Medicina Interna e Terapia Medica, Pavia, Italy; ³Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan; ⁴Mahatma Gandhi Mission Medical College, Navi Mumbai, India; ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Department of Clinical Immunology and Rheumatology, Lucknow, India; ⁶Royal Melbourne Hospital, Department of Rheumatology, Parkville, Australia; ⁷Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; ⁸University of Melbourne, Department of Medical Biology, Parkville, Australia; ⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India; ¹⁰Mymensingh Medical College, Mymensingh, Bangladesh; ¹¹Universiti Kebangsaan Malaysia, Faculty of Medicine, Kuala Lumpur, Malaysia; ¹²Faculty of Medicine Siriraj Hospital, Mahidol University, Division of Rheumatology, Department of Medicine, Bangkok, Thailand; ¹³Queen Savang Vadhana Memorial Hospital, Department of Medicine, Chonburi, Thailand; ¹⁴St. Luke's Medical Center-Global City, Department of Medicine, Section of Rheumatology, Taguig, Philippines; ¹⁵Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China; ¹⁶Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China; ¹⁷Maulana Azad Medical College, New Delhi, India; ¹⁸Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom; ¹⁹Salford Royal NHS Foundation Trust, Manchester Centre for Clinical Neurosciences, Salford, United Kingdom; ²⁰Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom; ²¹Royal National Hospital for Rheumatic Diseases, (at Royal United Hospitals), Bath, United Kingdom; ²²University of Bath, Department of Pharmacy and Pharmacology, Bath, United Kingdom; ²³Rayne Institute, University College London, Department of Rheumatology, Division of Medicine, London, United Kingdom; ²⁴University College London, Centre for Adolescent Rheumatology Versus Arthritis at UCL, London, United Kingdom; ²⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom; ²⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; ²⁷Saint-Joseph University, Rheumatology Department, Beirut, Lebanon; ²⁸Hotel-Dieu de France Hospital, Rheumatology Department, Beirut, Lebanon; ²⁹Pomeranian Medical University in Szczecin, Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology, Szczecin, Poland; ³⁰General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Department of Internal Medicine, Mexico City, Mexico; ³¹Hospital Universidad del Norte, Department of Medicine, Barranquilla, Colombia; ³²COVAD Study Group, Lucknow, India; ³³University of Pittsburgh School of Medicine, Division of Rheumatology and Clinical Immunology, Pittsburgh, United States of America; ³⁴Royal Wolverhampton Hospitals NHS Trust, Department of Rheumatology, Wolverhampton, United Kingdom; ³⁵Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham, United Kingdom

Background: Rheumatoid arthritis (RA) and spondyloarthritis, including either Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS), are some of the most diagnosed autoimmune rheumatic diseases (AIRDs) in rheumatologists' routine clinical practice [1]. Understanding patients' health and functional status is crucial to provide personalized management strategies to optimize disease control and enhance the quality of life.

Objectives: We aimed to compare disease burden in patients with RA, PsA or AS by assessing Patient-Reported Outcome Measurement Information System (PROMIS) Physical Health, Global Mental Health, Physical Function and Fatigue 4a together with VAS Pain.

Methods: Data were obtained in the international COVID vaccination in autoimmune rheumatic diseases study second e-survey (COVAD study). Demographics, AIRD diagnosis, disease activity, PROMIS Global Physical health, PROMIS Global Mental Health, PROMIS Physical Function SF10 and PROMIS Fatigue 4a score were extracted from the COVAD study database. For this study, we only included patients with self-reported RA or spondyloarthritis (either PsA or AS) undergoing active treatment with conventional synthetic disease-modifying drugs (DMARDs) and/or biologic DMARDs, who answered all the survey questions. Active disease was defined as the patient's perception of their disease as active in the four weeks before their first COVID-19 vaccine shot. Analysis of Variance with Bartlett's and Tukey's test was used to compare continuous variables between groups.

Results: From January to June 2022, n.1907 patients with RA, female 87.62% (1671/1907), with mean age ($\pm$ SD) 50.95 $\pm$ 13.67, n.311 patients with PsA, female 67.20% (209/311), with a mean age of 50.42 $\pm$ 12.70, and n.336 patients with AS, male 51.31% (209/311), with a mean age of 43.13 $\pm$ 12.75 years, responded to the COVAD e-survey. In those with active disease, neither physical health, global mental health, physical function, fatigue, nor pain were different among groups